291 related articles for article (PubMed ID: 30229547)
1. Novel Biomarkers for Prostate Cancer Detection and Prognosis.
Filella X; Foj L
Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
6. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
8. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
9. Emerging biomarkers in the diagnosis of prostate cancer.
Filella X; Fernández-Galan E; Fernández Bonifacio R; Foj L
Pharmgenomics Pers Med; 2018; 11():83-94. PubMed ID: 29844697
[TBL] [Abstract][Full Text] [Related]
10. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
12. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
13. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
14. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
15. [New biomarkers in serum and urine for detection of prostate cancer].
Stephan C; Jung K; Miller K; Ralla B
Aktuelle Urol; 2015 Mar; 46(2):129-43. PubMed ID: 25897535
[TBL] [Abstract][Full Text] [Related]
16. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
17. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
18. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
19. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
[TBL] [Abstract][Full Text] [Related]
20. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]